Key facts
- Notable investors include Creative Destruction Lab, University of Toronto, European Union, University of Toronto Entrepreneurship, Innovatiefonds Noord-Holland — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for Phosphoenix
- ·The full record, as it builds
Funding rounds
No funding rounds for Phosphoenix are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Phosphoenix
Developer of a chronically implanted wireless device aimed at restoring functional and life-enhancing vision for individuals who have lost it. The company's device bypasses the eyes and establishes a direct interface with the brain, leveraging fundamental neuroscience insights to deliver practical clinical applications, enabling users to recognize objects, navigate more independently, and enjoy an elevated quality of life by restoring rudimentary vision.
- Sector
- Healthcare
- HQ
- Amsterdam, Netherlands
- Founded
- 2019
- Employees
- 10
- Website
- phosphoenix.nl/
- Ownership
- Privately Held (backing)
Phosphoenix doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Phosphoenix shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Phosphoenix in its N-PORT filings yet. We sweep new filings monthly.